03/08/2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Laurent Peyrin-Biroulet et al. DLD 2024
21/01/2024
Vedolizumab for the Treatment of Chronic Pouchitis
N ENGL J MED 388;13 nejm.org March 30, 2023
13/10/2023
The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review
DLD 2023
20/08/2023
Management of inflammatory bowel disease in the elderly: A review
DLD Digestive and Liver Disease 55 (2023) 1001–1009
18/07/2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
NEJM
04/06/2023
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
NEJM - E.V. Loftus, Jr., J. Panes, A.P. Lacerda, L. Peyrin‑Biroulet, G. D’Haens, R. Panaccione, W. Reinisch, E. Louis, M. Chen, H. Nakase, J. Begun, B.S. Boland, C. Phillips, M.-E.F. Mohamed, J. Liu, Z. Geng, T. Feng, E. Dubcenco, and J.-F. Colombel
31/05/2023
Use of biologics for the management of Crohn’s disease: IG-IBD technical review based on the GRADE methodology
Digestive and Liver Disease: June 2023 (Volume 55, Issue 6)
31/05/2023
Prevention of post-operative recurrence of Crohn’s disease among patients with prior anti-TNF αfailure: A retrospective multicenter study
Digestive and Liver Disease: June 2023 (Volume 55, Issue 6)
28/04/2023
Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis
Digestive and Liver Disease 55 (2023) 580–586
10/03/2023
Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
OP08 at ECCO 18th - Jairath, V.; Feagan, B.G.; Danese, S.; Gionchetti, P.; Travis, S.
28/01/2023
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn’s disease: Results from the ENEIDA registry
ENEIDA registry by GETECCU
04/12/2022
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors
Onali S, et al. Am J Gastroenterol . 2022 Aug 1;117(8):1279-1287.
12/10/2022
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
Clinical Gastroenterology and Hepatology 2022
27/09/2022
Mistakes in the management of postoperative Crohn’s disease and how to avoid them
UEG education - Eugeni Domènech and Míriam Mañosa
07/08/2022
Segmental Versus Total Colectomy for Crohn’s Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study
Pellino G, Rottoli M, Mineccia M, Frontali A, Celentano V, Colombo F, Baldi C, Ardizzone S, Poggioli G, Sampietro GM, et al. JCC 2022
21/07/2022
Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
CGH 2022
20/07/2022
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
UEG Journal
11/06/2022
COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation
Clinical Gastroenterology and Hepatology, June 2022
13/04/2022
PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.
UEG Journal
08/03/2022
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial
William J. Sandborn, Bruce E. Sands, Stephen B. Hanauer, Subrata Ghosh, Jean-Frederic Colombel,j Brian G. Feagan, and John P. Lynch CGH2022
15/02/2022
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Authors: Peter M Irving, Krisztina B Gecse - Gastroenterology February 2022
05/01/2022
Upadacitinib Was Efficacious and Well Tolerated Over 30 Months in Patients with Crohn’s Disease in the CELEST Extension Study
Clinical Gastroenterology and Hepatology - Geert D’Haens, Julian Panés, Edouard Louis, Ana Lacerda, Qian Zhou, John Liu,Edward V. Loftus, Jr.
30/12/2021
COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation
Clinical Gastroenterology and Hepatology 12.2021
04/11/2021
Mistakes in colonoscopic surveillance in IBD and how to avoid them
UEG Education, 2021 - Matthew D Rutter
01/10/2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
William J. Sandborn et al., NEJM September 30th, 2021
28/08/2021
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
Séverine Vermeire, William J Sandborn et al. Journal of Crohn's and Colitis, 17 August 2021
04/08/2021
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis
Neeraj Narula, MD, MPH, FRCPC, Jean-Frederic Colombel, MD, Walter Reinisch, MD, PhD Published CGH July 27, 2021 DOI:https://doi.org/10.1016/j.cgh.2021.07.038
03/07/2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study
Journal of Crohn's and Colitis, 02 June 2021 Marc Ferrante, Brian G Feagan, et al.
05/06/2021
Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn’s Disease in Endoscopic Remission.
Clinical Gastroenterology and Hepatology June_2021 - Anne B. Hu, William Tan,Vikram Deshpande, and Ashwin N. Ananthakrishnan.
11/05/2021
STRIDE II An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Gastroenterology, 04/2021
04/04/2021
Ultrasonography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study
E. Calabrese, A. Rispo, F. Zorzi, E. De Cristofaro, A. Testa, G. Costantino, A. Viola, C. Bezzio, C. Ricci, S. Prencipe, C. Racchini, G. Stefanelli, M. Allocca, M. Cappello, G. Maconi, A. Spagnoli, G. Monteleone, F. Castiglione et al
03/03/2021
Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial
Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Feagan BG, Lynch JP. Clinical Gastroenterology and Hepatology (2021), doi: https://doi.org/10.1016/j.cgh.2021.02.025.
17/02/2021
Ustekinumab for Ulcerative colitis
Reena Khanna, MD, Waqqas Afif, MD. Gastroenterology (2021) https://doi.org/10.1053/j.gastro.2021.02.002.
28/01/2021
Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study
Pierre-Antoine Laurain ∗ Laurent Peyrin-Biroulet. Clinical Gastroenterology and Hepatology January 21, 2021 - DOI: https://doi.org/10.1016/j.cgh.2021.01.028
26/10/2020
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis
Gastroenterology, June 2020
09/04/2020
Efficacia nella vita reale di Tofacitinib in pazienti con colite ulcerosa refrattaria
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis Lair-Mehiri L, Digestive and Liver Disease, 2020-03-01,52 (3) 268-273
16/01/2020
Vedolizumab versus Adalimumab nel trattamento della colite ulcerosa moderato-severa – studio VARSITY
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE et al. N.Engl J Med 2019;381:1215-26
25/11/2019
Ustekinumab come terapia di induzione e mantenimento in pazienti affetti da rettocolite ulcerosa - studio UNIFI
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Sands BE et al. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750
21/04/2019
Monitoraggio dei livelli terapeutici di farmaci biologici ed anticorpi anti farmaco in pazienti con malattie infiammatorie croniche intestinali
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Papamichael K et al. Clin Gastroenterol Hepatol. 2019 Mar 27
20/01/2019
Efficacia del trapianto fecale sulla remissione a 8 settimane in paziente affetti da rettocolite ulcerosa
Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. Costello SP et al. JAMA. 2019 Jan 15;321(2):156-164
08/06/2018
Ripetute colonscopie di sorveglianza negative sono predittive di un basso rischio di CCR in pazienti con colite long-standing
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis
05/05/2018
Rischio di infezioni severe ed opportunistiche in corso di trattamento per malattie infiammatorie intestinali
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Kirchgesner J et al. Gastroenterology. 2018 Apr 12. [Epub ahead of print]
24/04/2018
Lo switch ad Infliximab biosimilare è sicuro e ben tollerato in pazienti con IBD in remissione (studio SECURE)
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trialStrik AS et al.
12/01/2018
Morgensen (GED-0301) è efficace sugli outcome sia clinici che endoscopici a 12 settimane in pazienti con malattia di Crohn in fase attiva
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.Feagan BG et al. Gastroenterology. 2018 Jan;154(1):61-64
30/12/2017
La colonscopia con endoscopi ad alta definizione è sovrapponibile alla cromoendoscopia nella sorveglianza delle coliti long standing
A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. Iacucci M et al. Am J Gastroenterol. 2017 Nov 14. [Epub ahead of print]
15/11/2017
Indicatori di risposta sub-ottimale a terapia con anti-TNF nelle IBD
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Lindsay JO, Armuzzi A, Gisbert JP et al. Dig Liver Dis. 2017 Oct;49(10):1086-1091
28/08/2017
Efficacia e sicurezza di anticorpi anti MAdCAM nel trattamento della colite ulcerosa: lo studio TURANDOT
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.Vermeire S et al. Lancet. 2017 Jul 8;390(10090):135-144. doi: 10.1016/S0140-6736(17)30930-3. Epub 2017 May 17.
20/07/2017
I livelli sierici di Infliximab all'induzione sono predittivi della risposta o del fallimento della terapia durante il mantenimento
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Liefferinckx C et al. Inflamm Bowel Dis. 2017 Aug;23(8):1371-1381
07/05/2017
MEDI2070, anticorpo monoclonale anti-IL23 efficace nella malattia di Crohn moderato-severa
Sands BE et al. Efficacy and Safety of MEDI2070, an antibody against interleukin 23, patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology. 2017 Apr 5. [Epub ahead of print]
07/04/2017
Efficacia del trapianto fecale da donatori multipli nella colite ulcerosa in fase di attività
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Paramsothy S et al. Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4.
06/02/2017
Remissione clinica in pazienti con malattia di Crohn moderato-severa trattati con Filgotinib
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017 Jan 21;389(10066):266-275.
01/01/2017
La sorveglianza endoscopica con biopsie mirate identifica un tasso simile di neoplasia rispetto alle biopsie random nei pazienti con RCU long-standing
Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Watanabe T et al. Gastroenterology. 2016 Dec;151(6):1122-1130.
13/11/2016
Cellule staminali mesenchimali derivate da tessuto adiposo nel trattamento delle fistole perianali complesse nella malattia di Crohn
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease:a phase 3 randomised, double-blind controlled trial. Panés J et al. Lancet 2016 Sep 24;388(10051):1281-90
13/11/2016
Cellule stromali mesenchimali autologhe derivate da midollo nella malattia di Crohn: trial di fase 1
The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease – a phase 1 trial with three doses. Aliment Pharmacol Ther. 2016 Sep;44(5):471-8
07/09/2016
Efficacia e sicurezza real-world di Vedolizumab nella malattia di Crohn moderato-severa (coorte USA)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium.
Dulai PS et al. Am J Gastroenterol. 2016 Aug;111(8):1147-55
07/09/2016
Terapia di induzione con Vedolizumab per le malattie infiammatori intestinali nella pratica clinica (coorte europea)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Baumgart DC et al. Aliment Pharmacol Ther. 2016 May;43(10):1090-102.
14/07/2016
Effetto della terapia di induzione con anti-TNF α sullo stato nutrizionale e sull'introito dietetico nella malattia infiammatoria intestinale
The Effect of anti-TNFa Induction Therapy on the Nutritional
Status and Dietary Intake in Inflammatory Bowel Disease,Csontos AA et al, J Gastrointestin Liver Dis, 2016;25(1):49-56
11/07/2016
Infliximab riduce la recidiva endoscopica, ma non quella clinica, dopo resezione ileocolica per malattia di Crohn
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection. Regueiro M et al. Gastroenterology. 2016 Jun;150(7):1568-78.
25/09/2013
Vedolizumab nel M. di Crohn
Vedolizumab as Induction and MaintenanceTherapy for Crohn’s Disease
23/09/2013
Vedolizumab nella Retto Colite Ulcerosa
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
21/02/2013
Flora intestinale ed IBD: un'altra prospettiva
V.Annese Scrive
21/02/2013
La infezione da Clostridium difficile si associa ad una aumentata mortalità anche a lungo termine nei pazienti con CU
Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis.Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Daneman N, Nguyen GC. Aliment Pharmacol Ther. 2012;36:1032-9.
21/02/2013
La metà dei pazienti con CD e ileo terminale normale alla ileocolonscopia può avere localizzazioni più prossimali della malattia
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy.
21/02/2013
Esiste correlazione fra remissione clinica e remissione endoscopica nei pazienti con colite ulcerosa?
Conclusioni diametralmente opposte da due studi differenti
21/02/2013
La seconda consensus ECCO sulla colite ulcerosa
Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis
21/02/2013
Nutrition and Crohn's disease
The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn’s disease treated with Infliximab
21/02/2013
Consensus canadese sulla terapia della colite ulcerosa grave
Treatment of hospitalized adult patients with severe ulcerative colitis: toronto consensus statements.Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R. Am J Gastroenterol. 2012;107:179-94
21/02/2013
Mesalazina: più efficace la terapia combinata orale/topica della sola terapia orale (sia in fase attiva, sia nel mantenimento) - la conferma da una meta-analisi
Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis.Ford AC, Khan KJ, Achkar JP, Moayyedi P. Am J Gastroenterol. 2012;107:167-76.
21/02/2013
Non trascurabile l'incidenza di complicanze postoperatorie dopo colectomia per colite ulcerosa
Postoperative complications and mortality following colectomy for ulcerative colitis
21/02/2013
L'FDA ha approvato Remicade per il trattamento della colite ulcerosa
L’FDA ha approvato Remicade ( Infliximab ) nel trattamento della colite ulcerosa, forma moderata-severa. L’approvazione è avvenuta grazie ai risultati degli studi clinici ACT1 e ACT2.
21/02/2013
RCU: l'endoscopia aiuta a predire il rischio di cancro!!!
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk . M D Rutter, B P Saunders, K H Wilkinson, S Rumbles, G Schofield, M A Kamm, C B Williams, A B Price, I C Talbot, A Forbes. Gut 2004;53:1813-1816
21/02/2013
Aumentata incidenza di infezione da enterococco vancomicina resistente nei pazienti con IBD ospedalizzati
Increased risk of vancomycin-resistant enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2011;17:1338-42.
21/02/2013
Adalimumab nella malattia di Crohn steroido-dipendente: un'ulteriore conferma della maggior efficacia dell'induzione col dosaggio maggiore (160/80)
Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit. Orlando A, Renna S, Mocciaro F, Cappello M, Di Mitri R, Randazzo C, Cottone M. Inflamm Bowel Dis. 2012;18:826-31.
21/02/2013
Una meta-analisi conferma l'efficacia (anche se modesta) delle tiopurine nella prevenzione delle recidive post-chirurgiche della malattia di Crohn
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis
10/01/2013
Il cotrattamento con immunosoppressori durante i primi sei mesi sembrerebbe vantaggioso anche nei pazienti in terapia con adalimumab
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S.Aliment Pharmacol Ther. 2012;36(11-12):1040-8.
10/01/2013
Aumentato rischio di complicanze perioperatorie anche nei pazienti con malattia di Crohn in terapia con anti-TNF: lo rivela una metaanalisi
Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Inflamm Bowel Dis. 2012;18:2404-13.
10/01/2013
Uno studio su popolazione chiarisce diversi aspetti del cancro colorettale associato ad IBD
Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008).Peyrin-Biroulet L, Lepage C, Jooste V, Guéant JL, Faivre J, Bouvier AM. Inflamm Bowel Dis. 2012;18:2247-51
10/01/2013
Strategia top-down nei pazienti con malattia di Crohn: un dato a favore (ma piuttosto discutibile) da uno studio su database amministrativi
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.Rubin DT, Uluscu O, Sederman R. Inflamm Bowel Dis. 2012;18:2225-31.
10/01/2013
Gli anticorpi anti-infliximab non sempre si associano a perdita di risposta
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA. Inflamm Bowel Dis. 2012;18:2209-17
10/01/2013
Il 10 per cento dei pazienti con displasia di basso grado sviluppa forme più avanzate di neoplasia, ma nel 40 per cento di quelli con displasia monofocale il reperto non viene successivamente confermato
Prospective study of the progression of low-grade dysplasia in ulcerative olitis using current cancer surveillance guidelines.Zisman TL, Bronner MP, Rulyak S, Kowdley KV, Saunders M, Lee SD, Ko C, Kimmey MB, Stevens A, Maurer J, Brentnall TA. Inflamm Bowel Dis. 2012;18:2240-6.
26/07/2012
Aumentato rischio di melanoma nei pazienti con malattia di Crohn in terapia con farmaci biologici
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Gastroenterology. 2012;143:390-399.
05/07/2012
Gli statements IBD Ahead sull utilizzo delle terapie convenzionali nella malattia di Crohn
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel JF, Panaccione R. J Crohns Colitis. 2012;6:116-31.
01/07/2012
La storia naturale dei pazienti con IBD e colangite sclerosante: i dati della Cleveland Clinic
Navaneethan U et al Aliment Pharmacol Ther. 2012;35:1054-1063. Navaneethan U et al Aliment Pharmacol Ther. 2012;35:1045-1053. Navaneethan U et al. Gastrointest Endosc. 2012;75:1045-1054. Navaneethan U et al J Crohns Colitis. 2012;6:674-80. Navaneethan U et al. Clin Gastroenterol Hepatol. 2012;10:540-6.
30/06/2012
Ridimensionato (ma sempre significativamente aumentato) il rischio di carcinoma colorettale nei pazienti con colite ulcerosa
Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies.Jess T, Rungoe C, Peyrin-Biroulet L. Clin Gastroenterol Hepatol. 2012;10:639-45.
30/06/2012
Il 75 per cento delle lesioni displastiche identificate nel corso della sorveglianza dei pazienti con CU sono localizzate al colon sinistro
Dysplasia is more common in the distal than proximal colon in ulcerative colitis surveillance.Goldstone R, Itzkowitz S, Harpaz N, Ullman T.Inflamm Bowel Dis. 2012;18:832-7.
30/06/2012
Qualche dubbio sulla utilità della misurazione dei livelli di infliximab e degli anticorpi anti-infliximab per predire la risposta alla intensificazione del trattamento
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M. Inflamm Bowel Dis. 2012l;18:1199-206
30/06/2012
Limitatissima efficacia del metotrexate nelle lesioni psoriasiformi indotte da anti-TNF
Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.Buisson A, Cuny JF, Barbaud A, Schmutz JL, Bigard MA, Guéant JL, Peyrin-Biroulet L.. Aliment Pharmacol Ther. 2012y;35:1175-80
30/06/2012
L'anamesi non è sempre affidabile nell'identificazione dei pazienti protetti dall'infezione da zoster candidati a terapia con biologici
Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Kopylov U, Levin A, Mendelson E, Dovrat S, Book M, Eliakim R, Ben-Horin S. Aliment Pharmacol Ther. 2012;36:145-50.
30/06/2012
Fattibilità e sicurezza della terapia con anti-TNF nei pazienti con IBD con pregresso trapianto di fegato
The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. Aliment Pharmacol Ther. 2012;36:159-65.
29/02/2012
Frequente il coinvolgimento del tratto digestivo superiore nei pazienti con malattia di Crohn in età pediatrica
Upper gastrointestinal involvement in paediatric onset Crohn's disease: prevalence and clinical implications. Crocco S, Martelossi S, Giurici N, Villanacci V, Ventura A. J Crohns Colitis. 2012 ;6:51-5. Diagnostic yield of upper endoscopy in paediatric patients with Crohn's disease and ulcerative colitis. Subanalysis of the HUPIR registry. Kovacs M, Muller KE, Arato A, Lakatos PL, Kovacs JB, Varkonyi A, Solyom E, Polgar M, Nemes E, Guthy I, Tokodi I, Toth G, Horvath A, Tarnok A, Tomsits E, Csosz
29/02/2012
Decorso meno aggressivo della PCS associata alla malattia di Crohn rispetto alla PSC associata alla colite ulcerosa
A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease.Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SP, Chapman RW. J Crohns Colitis. 2012;6:174-81.
29/02/2012
Ansia e depressione nei pazienti con IBD: frequenti e sottovalutate
Do Inflammatory Bowel Disease patients with anxiety and depressive symptoms receive the care they need? Bennebroek Evertsz' F, Thijssens NA, Stokkers PC, Grootenhuis MA, Bockting CL, Nieuwkerk PT, Sprangers MA. J Crohns Colitis. 2012;6:68-76.
10/02/2012
Colite ulcerosa severa refrattaria allo steroide: ciclosporina piu' efficace di infliximab in singola infusione?
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study.
10/02/2012
Adalimumab a lungo termine (un anno) nella colite ulcerosa: i dati dello studio ULTRA-2
Adalimumab Induces and Maintains Clinical Remission in Patients With
10/02/2012
Elevato rischio di recidive dopo trattamento endoscopico di lesioni polipoidi nei pazienti con colite ulcerosa
Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy.Kisiel JB, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. Inflamm Bowel Dis. 2012 ;18:226-35.
08/02/2012
La budesonide MMX: una nuova arma nella terapia della colite ulcerosa?
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study.Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd. Gastroenterology. 2012 ;143:1218-1226
08/02/2012
Una metanalisi conferma che anche i risultati del Quantiferon possono essere inficiati da terapie immunosoppressorie concomitanti
Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis.Shahidi N, Fu YT, Qian H, Bressler B. Inflamm Bowel Dis. 2012;18:2034-42.
08/02/2012
L'efficacia della mesalazina nella chemioprevenzione del carcinoma colorettale: nessuna evidenza dagli studi su popolazioni
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Nguyen GC, Gulamhusein A, Bernstein CN. Am J Gastroenterol. 2012;107:1298-304
08/02/2012
Aumentato rischio di infezioni gravi nei pazienti co malattia di Crohn trattati con biologici: i dati aggiornati del TREAT registry
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. Am J Gastroenterol. 2012;107:1409-22.
08/02/2012
Aumentato rischio di complicanze nei pazienti con IBD sottoposti a colecistectomia
Presence of concomitant inflammatory bowel disease is associated with an increased risk of postcholecystectomy complications.Navaneethan U, Choure A, Venkatesh PG, Hammel J, Lin J, Goldblum JR, Manilich E, Kiran RP, Remzi FH, Shen B. Inflamm Bowel Dis. 2012;18:1682-8